English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, March 29, 2024
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Thursday, March 21, 2024
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Wednesday, March 6, 2024
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資
Thursday, February 29, 2024
エーザイ、第18回アルツハイマー・パーキンソン病学会(AD/PDTM2024)において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表
Wednesday, February 21, 2024
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Wednesday, July 31, 2019
エーザイ、E2082の臨床第I相試験(治験)における死亡例の発生について

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575